Navigation Links
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
Date:7/2/2009

LEUVEN, Belgium and LUND, Sweden, July 3 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of a second cohort of patients for their Phase II trial of TB-402. This follows completion of recruitment of the first cohort of 100 patients ahead of schedule. TB-402 is a novel, long acting anticoagulant that is being developed for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery. The decision to move ahead with the second cohort of this trial follows unanimous advice from the external efficacy and safety monitoring board to proceed using a higher dose of TB-402.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study is assessing three different doses of TB-402 given as a single intravenous bolus injection post knee replacement surgery, and will enrol a total of 300 patients across 36 centers, mainly in Europe. The objective of the study is to assess the safety and efficacy of the three escalating doses of TB-402.

TB-402 is a recombinant human monoclonal antibody that partially inhibits Factor VIII, a key component of the coagulation cascade. This novel mode of action is expected to reduce the risk of undesirable bleeding events, even at high doses, as well as the need for patient monitoring. These are the two main drawbacks associated with current anticoagulants. In addition, TB-402 is a long-acting agent, which means it could be given as a single dose after surgery to prevent the development of DVT. This would be an attractive option, as all current anticoagulant treatment options require daily treatment for up to several weeks.

Professor Peter Verhamme from the University of Leuven will present additi
'/>"/>

SOURCE ThromboGenics NV and BioInvent International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. InterMune Announces Start of Phase 1b Trial of ITMN-191
11. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... 2014  BC Technical, the largest nationwide, non-OEM provider ... Inc., a leading provider of Siemens Nuclear Medicine and ... naming BC Technical as the authorized provider of service ... and BC Technical announced today that the two companies ... as the service and systems provider for MiE,s camera ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... 2011 ChromaDex Corporation (OTCBB: CDXC), an innovative ... and ingredients to the dietary supplement, food & ... results for the second quarter of 2011. On ... U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex ...
... NEW YORK, Aug. 11, 2011 Citeline, an Informa ... pharmaceutical clinical trials recently reviewed the findings from the ... July 16-21, 2011, noting that while pharma continues to ... ahead in terms of biomarkers and early warning for ...
Cached Medicine Technology:ChromaDex Announces Financial Results for Second Quarter 2011 2ChromaDex Announces Financial Results for Second Quarter 2011 3ChromaDex Announces Financial Results for Second Quarter 2011 4Global Standardization for Alzheimer's Biomarkers Moves a Major Step Closer to Reality 2
(Date:7/13/2014)... BC (PRWEB) July 13, 2014 Victorian ... excitement by promoting the rental of bikes for its ... historic downtown Victorian Hotel to tour the area using ... plus tax. Bicycle enthusiasts love to call Vancouver home, ... options for cycle travel and picturesque journeys through the ...
(Date:7/13/2014)... 2014 The report “Micronutrient Market ... Form (Chelated & Non Chelated), Application Mode (Soil, ... Trends and Forecast to 2018” defines and segments ... and forecasting of the global value and volume ... and restraining factors for the global agriculture micronutrients ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 According ... Processing and Computing Market by Component (processor, GPU, ... Automotive, MDA, Medical), and Geography - Forecast and ... Heterogeneous Mobile Processing & Computing Market is expected ... a CAGR of 20.75% from 2014 to 2020. ...
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... type of sensor for people with diabetes is being developed ... of blood, researchers report. Scientists at Brown University in ... artificial saliva. It uses light, metal and a special enzyme ... knows that diabetics have to prick their fingers to draw ...
(Date:7/13/2014)... York, New York (PRWEB) July 13, 2014 ... lawsuits ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson ... litigation’s second bellwether trial, which is expected to get ... Order issued in the U.S. District Court, Southern District ... Conference will be held on August 7, 2014 at ...
Breaking Medicine News(10 mins):Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
... , This release is available in German ... Foundation) establishes four new Research Units. This decision has just ... meeting in Bonn in April. In Research Units, outstanding researchers ... locations and across disciplines. The DFG funding thereby secures the ...
... , WEDNESDAY, April 20 (HealthDay News) -- Excessive sleeping, ... a greatly increased risk for behavioral problems later in ... describe as "regulatory problems," were the focus of an ... Data came from 16,848 children, including 1,935 with regulatory ...
... at the Mailman School of Public Health report evidence of ... deficits in IQ and working memory at age seven. ... prenatal chlorpyrifos exposure on cognitive development at the time of ... Perspectives . Until banned for indoor residential use ...
... , WEDNESDAY, April 20 (HealthDay News) -- ... family instability has no effect, a new study suggests. ... children and their families when the children were 9 ... provided insight into family poverty, family transitions, family demographics ...
... WEDNESDAY, April 20 (HealthDay News) -- Researchers have developed a ... pregnant women will deliver their babies prematurely. The ... foolproof: a study found that it misses some premature births ... an important tool for an obstetrician who currently has no ...
... , WEDNESDAY, April 20 (HealthDay News) -- Inhaled ... patients with chronic obstructive pulmonary disease, or COPD, who ... U.S. researchers examined the medical records of 15,768 ... VA hospitals for pneumonia between 2002 and 2007. Of ...
Cached Medicine News:Health News:DFG establishes 4 new research units 2Health News:DFG establishes 4 new research units 3Health News:Babies' Persistent Fussiness Could Mean Behavioral Woes Ahead 2Health News:Prenatal exposure to common insecticide linked to decreases in cognitive functioning at age 7 2Health News:Poverty Can Hinder a Child's Cognitive Development, Study Says 2Health News:Experimental Test May Warn of Premature Births 2Health News:Inhaled Meds May Save COPD/Pneumonia Patients' Lives 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: